Kuros Biosciences Ltd.

Quarterly Report • Apr 22, 2009

News Details

Corporate | 22 April 2009 17:35

Cytos Biotechnology AG: First Quarter Report 2009

Cytos Biotechnology AG / Quarter Results

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Cytos Biotechnology Ltd First Quarter Report 2009 as of March 31, 2009

Summary of Q1 2009

• Cytos Biotechnology announced alignment of resources following a
  setback in the development of its hypertension vaccine CYT006-AngQb

• Recruitment of allergic patients for phase IIb dose-finding study with
  CYT003-QbG10 completed

• Upcoming events

  - Presentation of phase II study results for CYT003-QbG10
    monotherapy at the XXVIII Congress of the European Academy of
    Allergy and Clinical Immunology, June 9, 2009, Warsaw, Poland
  
  - Company presentation at the 6th Annual Bank of America-Merrill
    Lynch Pan-European Biotech/Medtech Conference, May 19, 2009,
    London, UK
  

• Financial summary

                                 Q1 2009          Q1 2008
  

  Revenues CHF million 0.3 0.3
  Net operating costs CHF million (11.0) (10.5)
  Net loss CHF million (11.8) (10.2)

                                 March 31, 2009   December 31, 2008
  

  Cash, cash equivalents, CHF million 87.9 98.0
  financial assets
  and trade receivables

Full-time employees number 133 132

The complete First Quarter Report can be downloaded on Cytos
Biotechnology's website under the following link:

http://www.cytos.com/userfiles/file/Cytos_Q1_2009_E.pdf

About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of different
Immunodrug(TM) candidates in various disease areas, of which five are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer, and Pfizer
Animal Health. Founded in 1995 as a spin-off from the Swiss Federal
Institute of Technology (ETH) in Zurich, the company is located in
Schlieren (Zurich). Currently, the company has 133 employees. Cytos
Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

Jakob Schlapbach, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Wagistrasse 25, Postfach
CH-8952 Schlieren (Zurich)
Tel. +41 44 733 46 46
Fax. +41 44 733 47 02
e-mail: jakob.schlapbach@cytos.com
www.cytos.com
22.04.2009 Financial News transmitted by DGAP

---

Language: English
Issuer: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
WKN: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open Market in
Frankfurt; Foreign Exchange(s) SWX

End of News DGAP News-Service

---